Health Catalyst (HCAT)
(Delayed Data from NSDQ)
$7.15 USD
+0.10 (1.42%)
Updated Aug 21, 2024 04:00 PM ET
After-Market: $7.16 +0.01 (0.14%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Price, Consensus and EPS Surprise
HCAT 7.15 +0.10(1.42%)
Will HCAT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HCAT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HCAT
Health Catalyst (HCAT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Health Catalyst (HCAT) Tops Q2 Earnings and Revenue Estimates
HCAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Time to Play 5 Top-Ranked Stocks With Rising P/E?
Do Options Traders Know Something About Health Catalyst (HCAT) Stock We Don't?
Zacks Industry Outlook Highlights Hims & Hers Health, Enovis Corp and Health Catalyst
Other News for HCAT
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Progyny (PGNY) and Health Catalyst (HCAT)
Health Catalyst (HCAT) Receives a Buy from Barclays
Cantor Fitzgerald Remains a Buy on Health Catalyst (HCAT)
RBC Capital Reaffirms Their Hold Rating on Health Catalyst (HCAT)
The Analyst Verdict: Health Catalyst In The Eyes Of 5 Experts